ImmuCell (NASDAQ:ICCC) Shares Cross Above 200 Day Moving Average – Time to Sell?

Shares of ImmuCell Corporation (NASDAQ:ICCC) crossed above its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $9.77 and traded as high as $10.37. ImmuCell shares last traded at $10.25, with a volume of 11,335 shares changing hands.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ICCC. Weiss Ratings raised shares of ImmuCell from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, October 19th. Wall Street Zen upgraded shares of ImmuCell to a “strong-buy” rating in a research note on Saturday, June 27th. One investment analyst has rated the stock with a Hold rating. According to MarketBeat, the stock presently has an average rating of “Hold”.

ImmuCell Stock Down 1.8%

The business has a fifty day moving average price of $10.00 and a two-hundred day moving average price of $9.77. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.75 and a quick ratio of 2.71. The firm has a market capitalization of $93.07 million, a price-to-earnings ratio of 128.14 and a beta of 0.56.

ImmuCell (NASDAQ:ICCC) last announced its quarterly earnings data on Thursday, August 13th. The biotechnology company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.05 by $0.15. The business had revenue of $7.19 million during the quarter, compared to analysts’ expectations of $5.40 million. ImmuCell had a net margin of 2.57% and a return on equity of 2.69%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in ImmuCell stock. Militia Capital Management LLC purchased a new stake in ImmuCell Corporation (NASDAQ:ICCC) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 18,000 shares of the biotechnology company’s stock, valued at approximately $114,000. Militia Capital Management LLC owned about 0.20% of ImmuCell as of its most recent filing with the Securities and Exchange Commission (SEC). 13.47% of the stock is owned by hedge funds and other institutional investors.

ImmuCell Company Profile

ImmuCell Corporation is a biotechnology and animal health company headquartered in Portland, Maine. The company develops, manufactures, and commercializes products designed to support the health and productivity of livestock, with a primary focus on cattle.

ImmuCell’s products include FirstStep Calf Health, an on-farm diagnostic test that helps dairy and beef producers assess whether newborn calves have received adequate passive immunity from colostrum. The company also develops antibody-based products intended to help prevent or manage common diseases affecting young livestock, including neonatal calf diarrhea.

Founded in 1987, ImmuCell serves the animal health market in the United States and has pursued regulatory approvals and commercial partnerships to expand the availability of its products.